Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05884775 · ClinicalTrials.gov registry record · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
A NA study of Type 2 Diabetes, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 353
- Enrollment target
- 1
- Study location
NCT05884775: Recruiting NA study of Type 2 Diabetes, sponsored by NYU Langone Health.
NCT05884775 is a NA study of Type 2 Diabetes that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 353 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05884775, a NA study of Type 2 Diabetes, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 353 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D).
Primary Outcome
HbA1c will be extracted from lab data available within the EHR
Conditions Studied
Interventions
- OTHER Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2028-05-31 |
| Phase | NA |
What NCT05884775 shows while recruiting
NCT05884775 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool is the first listed.
NCT05884775 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05884775 about?
NCT05884775 is a clinical study titled "Novel Digital Patient-Reported Outcomes Tool for Diabetes Management". Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D).
What is the current status of trial NCT05884775?
This trial is currently recruiting. It is a NA study. The enrollment target is 353 participants. The study started on 2025-11-04. Estimated completion is 2028-05-31.
What conditions does trial NCT05884775 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT05884775?
The interventions under investigation include: Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool (OTHER).
Who is sponsoring clinical trial NCT05884775?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05884775 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05884775's enrollment target sits among peer trials
353 57th of 327 higher than 270 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI